Christos Chouaid

OncopneumologueProfesseur

Enseignants chercheurs

christos.chouaid@chicreteil.fr

Description

Pneumologue, spécialiste en oncologie thoracique et diplômé en Santé publique, Christos Chouaid est Professeur d’université à Paris XII, Créteil. Il est titulaire d’une thèse de Sciences en Santé Publique, obtenue à Paris VI. Il coordonne le GFPC (Groupe de Pneumo Cancérologie Clinique), un réseau de recherche académique regroupant une cinquantaine de centres spécialisés en France.

Il est particulièrement impliqué dans la recherche clinique sur données en vie réelle et a acquis une expertise dans le domaine de l’analyse médico-économique en oncologie thoracique reconnue au niveau nationale et internationale. Il est membre de plusieurs sociétés savantes, expert pour plus de 20 revues scientifiques dans le domaine de l’oncologie thoracique, des maladies respiratoires et de la médico-économie. Il est signataire de plus de 250 manuscrits indexés Medline.

Il est par ailleurs secrétaire générale de la Fondation du Souffle et président du Comité Nationale de lutte contre les Maladies Respiratoires, 2 organismes associatifs qui ont vocation a améliorer l’information sur les maladies respiratoires au niveau de la population générale.

Publications

2024

Hagege M, Bringuier M, Martinez-Tapia C, Chouaid C, Helissey C, Brain E, Lempdes GRochette, Dubot C, Bello-Roufai D, Geiss R, Kempf E, Gourden A, Elgharbi H, Garrigou S, Gregoire L, Derbez B, Canoui-Poitrine F. Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach. Age Ageing. 2024;53(2).

2023

Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, T Hiltermann JN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study. J Thorac Oncol. 2023;18(2):181-193.
Chouaid C, Monnet I, Auliac J-B. First-line management of advanced non-small-cell lung cancer: can we do better?. Transl Lung Cancer Res. 2023;12(7):1643-1648.
Lasvergnas J, Fallet V, Duchemann B, Jouveshomme S, Cadranel J, Chouaid C. PDL1-status predicts primary resistance of metastatic, EGFR-mutated non small cell lung cancers to EGFR tyrosine-kinase inhibitors. Respir Med Res. 2023;84:101018.
Bylicki O, Tomasini P, Radj G, Guisier F, Monnet I, Ricordel C, Bigay-Gamé L, Geier M, Chouaid C, Daniel C, Swalduz A, Toffart A-C, Doubre H, Peloni J-M, Moreau D, Subtil F, Grellard J-M, Castera M, Clarisse B, Martins-Lavinas P-H, Decroisette C, Greillier L. Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-. Eur J Cancer. 2023;183:38-48.
Gendarme S, Zebachi S, Corre R, Greillier L, Justeau G, Bylicki O, Decroisette C, Auliac J-B, Guisier F, Geier M, Ricordel C, Frelaut M, Paillaud E, Chouaid C, Canoui-Poitrine F. Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study. J Geriatr Oncol. 2023:101506.
Grambow-Velilla J, Seban R-D, Chouahnia K, Assié J-B, Champion L, Girard N, Bonardel G, Matton L, Soussan M, Chouaid C, Duchemann B. Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy. Cancers (Basel). 2023;15(8).
Chouaid C, Bosquet L, Girard N, Kron A, Scheffler M, Griesinger F, Sebastian M, Trigo J, Viteri S, Knott C, Rodrigues B, Rahhali N, Cabrieto J, Diels J, Perualila NJ, Schioppa CA, Sermon J, Toueg R, Erdmann N, Mielke J, Nematian-Samani M, Martin-Fernandez C, Pfaira I, Li T, Mahadevia P, Wolf J. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations. Adv Ther. 2023;40(3):1187-1203.
Descourt R, Greillier L, Perol M, Ricordel C, Auliac J-B, Falchero L, Gervais R, Veillon R, Vieillot S, Guisier F, Marcq M, Justeau G, Bigay-Gamé L, Bernardi M, Fournel P, Doubre H, Pinsolle J, Amrane K, Chouaid C, Decroisette C. First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study). Cancer Immunol Immunother. 2023;72(1):91-99.
Vergnenègre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaid C, Robinet G. Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo). Lung Cancer. 2023;178:191-197.
Assié J-B, Chouaid C, Nunes H, Reynaud D, Gaudin A-F, Grumberg V, Jolivel R, Jouaneton B, Cotté F-E, Duchemann B. Outcome following nivolumab treatment in patients with advanced non-small cell lung cancer and comorbid interstitial lung disease in a real-world setting. Ther Adv Med Oncol. 2023;15:17588359231152847.
Dhamelincourt E, Descourt R, Rousseau-Bussac G, Doubre H, Decroisette C, Demontrond P, Le Garff G, Falchero L, Huchot E, Vieillot S, Corre R, Kazulinski L, Bizieux A, Bigay-Gamé L, Morel H, Molinier O, Chouaid C, Guisier F. Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study). Target Oncol. 2023;18(6):905-914.
Decroisette C, Greillier L, Curcio H, Perol M, Ricordel C, Auliac J-B, Falchero L, Veillon R, Vieillot S, Guisier F, Marcq M, Justeau G, Bigay-Gamé L, Bernardi M, Doubre H, Pinsolle J, Amrane K, Chouaid C, Descourt R. Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study). J Immunother. 2023.
Assié J-B, Grumberg V, Reynaud D, Gaudin A-F, Batisse A, Jolivel R, Jouaneton B, Cotté F-E, Chouaid C. Characteristics, management, and healthcare resources of patients with advanced non-small-cell lung cancer surviving 5 years after nivolumab treatment initiation: A national database analysis. Respir Med Res. 2023;84:101051.
Babey H, Jamme P, Curcio H, Assié JBaptiste, Veillon R, Doubre H, Perol M, Guisier F, Huchot E, Decroisette C, Falchero L, Corre R, Cortot A, Chouaid C, Descourt R. Real-World Treatment Outcomes of MET Exon14 Skipping in Non-small Cell Lung Cancer: GFPC 03-18 Study. Target Oncol. 2023;18(4):585-591.

2022

Excoffier J-B, Salaün-Penquer N, Ortala M, Raphaël-Rousseau M, Chouaid C, Jung C. Analysis of COVID-19 inpatients in France during first lockdown of 2020 using explainability methods. Med Biol Eng Comput. 2022;60(6):1647-1658.
Jung C, Excoffier J-B, Raphaël-Rousseau M, Salaün-Penquer N, Ortala M, Chouaid C. Evolution of hospitalized patient characteristics through the first three COVID-19 waves in Paris area using machine learning analysis. PLoS One. 2022;17(2):e0263266.
Poucineau J, Delory T, Lapidus N, Hejblum G, Chouaid C, Le Cœur S, Khlat M. Hospital admissions and mortality for acute exacerbations of COPD during the COVID-19 pandemic: A nationwide study in France. Front Med (Lausanne). 2022;9:995016.
Griesinger F, Perol M, Girard N, Durand-Zaleski I, Zacharias S, Bosquet L, Jänicke M, Quantin X, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Reynaud D, Thomas M, Chouaid C. Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. Lung Cancer. 2022;172:65-74.
Grumberg V, Chouaid C, Cotté F-E, Jouaneton B, Jolivel R, Gaudin A-F, Reynaud D, Assié J-B, Borget I. Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. J Med Econ. 2022;25(1):691-699.
Goussault H, Gendarme S, Assié J-B, Jung C, Epaud S, Algans C, Salaün-Penquer N, Rousseau M, Lazatti A, Chouaid C. Risk factors for early mortality of lung cancer patients in France: A nationwide analysis. Cancer Med. 2022;11(24):5025-5034.
Van Sanden S, Murton M, Bobrowska A, Rahhali N, Sermon J, Rodrigues B, Goff-Leggett D, Chouaid C, Sebastian M, Greystoke A. Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis. Target Oncol. 2022;17(2):153-166.
Justeau G, Huchot E, Simonneau Y, Roa M, Le Treut J, Le Garff G, Bylicki O, Schott R, Bravard A-S, Tiercin M, Lamy R, De Chabot G, Marty A, Moreau D, Locher C, Bernier C, Chouaid C, Descourt R. Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. Lung Cancer. 2022;174:45-49.
Boussageon M, Swalduz A, Chouaid C, Bylicki O. First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors: New Combinations and Long-Term Data. BioDrugs. 2022;36(2):137-151.
Assié J-B, Crépin F, Grolleau E, Canellas A, Geier M, Grébert-Manuardi A, Akkache N, Renault A, Hauss P-A, Sabatini M, Bonnefoy V, Cortot A, Wislez M, Gauvain C, Chouaid C, Scherpereel A, Monnet I. Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. Cancers (Basel). 2022;14(6).
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cadranel J, Cortot ABenjamin, Guisier F, Galland L, Do P, Schott R, Dansin E, Arrondeau J, Auliac J-B, Geier M, Chouaid C. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study. Cancers (Basel). 2022;14(7).
Chouaid C, Grumberg V, Batisse A, Corre R, Levra MGiaj, Gaudin A-F, Prodel M, Lortet-Tieulent J, Assié J-B, Cotté F-E. Machine Learning-Based Analysis of Treatment Sequences Typology in Advanced Non-Small-Cell Lung Cancer Long-Term Survivors Treated With Nivolumab. JCO Clin Cancer Inform. 2022;6:e2100108.
Edelman MJ, Dvorkin M, Laktionov K, Navarro A, Juan-Vidal O, Kozlov V, Golden G, Jordan O, Deng CQ, Bentsion D, Chouaid C, Dechev H, Dowlati A, Núñez NFernández, Ivashchuk O, Kiladze I, Kortua T, Leighl N, Luft A, Makharadze T, Min YJ, Quantin X. Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. Lung Cancer. 2022;166:135-142.
Landre T, Justeau G, Assié J-B, Chouahnia K, Davoine C, Taleb C, Chouaid C, Duchemann B. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71(3):719-726.
Gendarme S, Bylicki O, Chouaid C, Guisier F. Fusions in Non-Small-Cell Lung Cancer: Evidence to Date. Curr Oncol. 2022;29(2):641-658.
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté F-E, Audigier-Valette C, Griesinger F. Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts. Cancers (Basel). 2022;14(24).
Garassino MC, Mazières J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Sánchez JGarcia, Velarde LEnrique Ch, Bernabe R, Paz-Ares L, Perez IDiaz, Trunova N, Foroutanpour K, Faivre-Finn C. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022;17(12):1415-1427.
Juarez-Garcia A, Sharma R, Hunger M, Kayaniyil S, Penrod JR, Chouaid C. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review. Lung Cancer. 2022;166:205-220.
Gendarme S, Pairon J-C, Andujar P, Laurent F, Brochard P, Delva F, Clin B, Gislard A, Paris C, Thaon I, Goussault H, Canoui-Poitrine F, Chouaid C. Cost-Effectiveness of an Organized Lung Cancer Screening Program for Asbestos-Exposed Subjects. Cancers (Basel). 2022;14(17).
Avrillon V, Daniel C, Boisselier P, Le Péchoux C, Chouaid C. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program. Lung. 2022;200(1):95-105.
Paleiron N, Gervais R, Rousseau-Bussac G, Game LBigay, Chiappa AMarie, Lamy R, Guisier F, Le Caer H, Robinet G, Bizieux A, Chouaid C. Management of patients with synchronous head-and-neck and lung cancers: SYNCHRON GFPC 15-01 study. J Cancer Res Ther. 2022;18(Supplement):S160-S164.

2021

Scotte F, Simon H, Laplaige P, Antoine E-C, Spasojevic C, Texier N, Gouhier K, Chouaid C. Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. BMJ Support Palliat Care. 2021.
Bylicki O, Rivière F, Tournier C, Canoui-Poitrine F, Grassin F, Margery J, Prodel M, Vainchtock A, Assié J-B, Chouaid C. Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care. Clin Lung Cancer. 2021;22(3):e320-e328.
Seban R-D, Assié J-B, Giroux-Leprieur E, Massiani M-A, Bonardel G, Chouaid C, Deleval N, Richard C, Mezquita L, Girard N, Champion L. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. Lung Cancer. 2021;159:45-55.
Girard N, Perol M, Simon G, Valette CAudigier, Gervais R, Debieuvre D, Schott R, Quantin X, Coudert B, Lena H, Carton M, Robain M, Filleron T, Chouaid C. Treatment strategies for unresectable locally advanced non-small cell lung cancer in the real-life ESME cohort. Lung Cancer. 2021;162:119-127.
Gounant V, Duruisseaux M, Soussi G, Van Hulst S, Bylicki O, Cadranel J, Wislez M, Trédaniel J, Spano J-P, Helissey C, Chouaid C, Molinier O, Dhalluin X, Doucet L, Hureaux J, Cazes A, Zalcman G. Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients. Cancers (Basel). 2021;13(5).
Chouaid C, Filleron T, Debieuvre D, Perol M, Girard N, Dansin E, Lena H, Gervais R, Cousin S, Otto J, Schott R, Planchard D, Madroszyk A, Kaderbhai C, Dubray-Longeras P, Hiret S, Pichon E, Clément-Duchêne C, Chenuc G, Simon G, Bosquet L, Quantin X. A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes. Target Oncol. 2021;16(6):801-811.
Gendarme S, Goussault H, Assié J-B, Taleb C, Chouaid C, Landre T. Impact on All-Cause and Cardiovascular Mortality Rates of Coronary Artery Calcifications Detected during Organized, Low-Dose, Computed-Tomography Screening for Lung Cancer: Systematic Literature Review and Meta-Analysis. Cancers (Basel). 2021;13(7).
Lamy T, Cabarrou B, Planchard D, Quantin X, Schneider S, Bringuier M, Besse B, Girard N, Chouaid C, Filleron T, Simon G, Baldini C. Biomarker Testing in Older Patients Treated for an Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer: The French ESME Real-Life Multicenter Cohort Experience. Cancers (Basel). 2021;14(1).
Martel-Lafay I, Monnet I, Lardy-Cleaud A, Danhier S, Salem N, Gallocher O, Fournel P, Chouaid C, Bylicki O. Feasibility of Stereotactic Body Radiation Therapy on Unresectable Stage III NSCLC with Peripheral Primary Tumor: A Prospective Study (GFPC 01-14). Curr Oncol. 2021;28(5):3804-3811.
Auliac J-B, Monnet I, Bizieux A, Greillier L, Geier M, Falchero L, Le Garff G, Lamy R, Guisier F, Ricordel C, Chouaid C, Vergnenègre A. Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study). Lung Cancer. 2021;161:122-127.
Matrat M, Gain M, Haioun C, Le Bras F, Nisse C, Morschhauser F, Clin B, Baldi I, Verdun-Esquer C, Garnier R, Laborde-Castérot H, Hérin F, Esquirol Y, Andujar P, Belacel M, Chouaid C, Chauvet C, Lasfargues G, Pairon J-C. Development of a Questionnaire for the Search for Occupational Causes in Patients with Non-Hodgkin Lymphoma: The RHELYPRO Study. Int J Environ Res Public Health. 2021;18(8).
Descourt R, Chouaid C, Perol M, Besse B, Greillier L, Bylicki O, Ricordel C, Guisier F, Gervais R, Schott R, Auliac J-B, Robinet G, Decroisette C. First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50. Future Oncol. 2021;17(23):3007-3016.
Vergnenègre A, Chouaid C. Economic analyses of immune-checkpoint inhibitors to treat lung cancer. Expert Rev Pharmacoecon Outcomes Res. 2021;21(3):365-371.
Monnet I, Vergnenègre A, Robinet G, Bérard H, Lamy R, Falchero L, Vieillot S, Schott R, Ricordel C, Chouabe S, Thomas P, Gervais R, Madroszyk A, Abdiche S, Chiappa AMarie, Greillier L, Decroisette C, Auliac JBernard, Chouaid C. Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. Ther Adv Med Oncol. 2021;13:17588359211006983.
de Climens FRoborel, Chouaid C, Poulet C, Leroy V, Stoven L, Cortot ABenjamin, Dhalluin X, Gauvain C. Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC. JTO Clin Res Rep. 2021;2(5):100147.
Goussault H, Gendarme S, Assié JBaptiste, Bylicki O, Chouaid C. Factors associated with early lung cancer mortality: a systematic review. Expert Rev Anticancer Ther. 2021;21(10):1125-1133.

2020

Bocciarelli C, Cohen J, Pelletier R, Van Nhieu JTran, Derman J, Favre L, Bourgogne A, Monnet I, Chouaid C, Pujals A. Evaluation of the Idylla system to detect the EGFR mutation using extracted DNA. Pathol Res Pract. 2020;216(1):152773.
Sanchis-Borja M, Ricordel C, Chiappa AMarie, Hureaux J, Odier L, Jeannin G, Descourt R, Gervais R, Monnet I, Auliac J-B, Chouaid C. Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort. Lung Cancer. 2020;143:36-39.
Landre T, Chouahnia K, Guetz GDes, Duchemann B, Assié J-B, Chouaid C. First-line immune-checkpoint inhibitor plus chemotherapy chemotherapy alone for extensive-stage small-cell lung cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920977137.
Girard N, Moro-Sibilot D, Bouée S, Emery C, Torreton E, Le Lay K, Luciani L, Maritaz C, Chouaid C. Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in -mutated non-small-cell lung cancer: a real life study. Future Oncol. 2020;16(16):1115-1124.
Landre T, Guetz GDes, Chouahnia K, Duchemann B, Assié J-B, Chouaid C. First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation. J Cancer Res Clin Oncol. 2020;146(12):3333-3339.
Bylicki O, Guisier F, Monnet I, Doubre H, Gervais R, Janicot H, Perol M, Fournel P, Lamy R, Auliac J-B, Chouaid C. Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine (Baltimore). 2020;99(3):e18726.
Seban R-D, Assié J-B, Giroux-Leprieur E, Massiani M-A, Soussan M, Bonardel G, Chouaid C, Playe M, Goldfarb L, Duchemann B, Girard N, Champion L. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer. Ann Nucl Med. 2020;34(12):968-974.
Chouaid C, Baize N, Monnet I. Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined. Transl Lung Cancer Res. 2020;9(5):1732-1735.
Landre T, Guetz GDes, Chouahnia K, Taleb C, Vergnenègre A, Chouaid C. First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.. J Cancer Res Clin Oncol. 2020;146(2):441-448.
Seban R-D, Assié J-B, Giroux-Leprieur E, Massiani M-A, Soussan M, Bonardel G, Chouaid C, Playe M, Goldfarb L, Duchemann B, Mezquita L, Girard N, Champion L. Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers (Basel). 2020;12(8).
Gendarme S, Chouaid C. Monitoring Subsolid Pulmonary Nodules in High-Risk Patients Is Even More Cost-Effective When Combined With a Stop-Smoking Program. J Thorac Oncol. 2020;15(8):1268-1270.
Guisier F, Dubos-Arvis C, Vinas F, Doubre H, Ricordel C, Ropert S, Janicot H, Bernardi M, Fournel P, Lamy R, Perol M, Dauba J, Gonzales G, Falchero L, Decroisette C, Assouline P, Chouaid C, Bylicki O. Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. J Thorac Oncol. 2020;15(4):628-636.
Amrane K, Geier M, Corre R, Lena H, Léveiller G, Gadby F, Lamy R, Bizec J-L, Goarant E, Robinet G, Gouva S, Quere G, Abgral R, Schick U, Bernier C, Chouaid C, Descourt R. First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study. Cancer Med. 2020;9(7):2309-2316.
Arpin D, Charpentier M-C, Bernardi M, Monnet I, Boni A, Watkin E, Goubin-Versini I, Lamy R, Gérinière L, Geier M, Forest F, Gervais R, Madrosyk A, Guisier F, Serrand C, Locher C, Decroisette C, Fournel P, Auliac J-B, Jeanfaivre T, Letreut J, Doubre H, François G, Piton N, Chouaid C, Damotte D. PD-L1-expression patterns in large-cell neuroendocrine carcinoma of the lung: potential implications for use of immunotherapy in these patients: the GFPC 03-2017 "EPNEC" study. Ther Adv Med Oncol. 2020;12:1758835920937972.
Vergnenègre A, Monnet I, Bizieux A, Bernardi M, Chiapa AMarie, Lena H, Chouaid C, Robinet G. Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC 04-2017). Future Oncol. 2020;16(4):5-10.
Assié J-B, Corre R, Levra MGiaj, Calvet CYannick, Gaudin A-F, Grumberg V, Jouaneton B, Cotté F-E, Chouaid C. Nivolumab treatment in advanced non-small cell lung cancer: real-world long-term outcomes within overall and special populations (the UNIVOC study). Ther Adv Med Oncol. 2020;12:1758835920967237.
Chouaid C, Monnet I, Baize N. Carboplatin plus etoposide for sensitive relapsed small-cell lung cancer - Authors' reply. Lancet Oncol. 2020;21(12):e546.
Auliac J-B, Bayle S, Do P, Le Garff G, Roa M, Falchero L, Huchot E, Quere G, Jeannin G, Métivier A-C, Hobeika J, Guisier F, Chouaid C. Efficacy of Dabrafenib Plus Trametinib Combination in Patients with V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019. Cancers (Basel). 2020;12(12).
Garassino MChiara, Cho B-C, Kim J-H, Mazières J, Vansteenkiste J, Lena H, Jaime JCorral, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Poole L, Wadsworth C, Dennis PA, Rizvi NA. Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. Lung Cancer. 2020;147:137-142.
Bylicki O, Paleiron N, Assié J-B, Chouaid C. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date. Onco Targets Ther. 2020;13:5691-5706.
Geier M, Descourt R, Corre R, Léveiller G, Lamy R, Goarant E, Bizec J-L, Bernier C, Quere G, Amrane K, Gaye E, Lucia F, Burte E, Chouaid C, Robinet G. Duration of nivolumab for pretreated, advanced non-small-cell lung cancer. Cancer Med. 2020;9(19):6923-6932.
Mayenga M, Assié J-B, Monnet I, Massiani M-A, Tabeze L, Friard S, Fraboulet S, Métivier A-C, Chouaid C, Zemoura L, Longchampt E, Callens C, Melaabi S, Couderc L-J, Doubre H. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases. Lung Cancer. 2020;150:21-25.
Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H, Vergnenègre A, Crequit J, Lamy R, Auliac J-B, Letreut J, Le Caer H, Gervais R, Dansin E, Madroszyk A, Renault P-A, Le Garff G, Falchero L, Bérard H, Schott R, Saulnier P, Chouaid C. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2020;21(9):1224-1233.
Levra MGiaj, Cotté F-E, Corre R, Calvet C, Gaudin A-F, Penrod JR, Grumberg V, Jouaneton B, Jolivel R, Assié J-B, Chouaid C. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 2020;140:99-106.
Owonikoko TK, Niu H, Nackaerts K, Csoszi T, Ostoros G, Mark Z, Baik C, Joy AAbraham, Chouaid C, Jaime JCorral, Kolek V, Majem M, Roubec J, Santos ES, Chiang AC, Speranza G, Belani CP, Chiappori A, Patel MR, Czebe K, Byers L, Bahamon B, Li C, Sheldon-Waniga E, Kong EF, Williams M, Badola S, Shin H, Bedford L, Ecsedy JA, Bryant M, Jones S, Simmons J, E Leonard J, Ullmann CDansky, Spigel DR. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. J Thorac Oncol. 2020;15(2):274-287.
Bennouna J, Girard N, Audigier-Valette C, Le Thuaut A, Gervais R, Masson P, Marcq M, Molinier O, Cortot A, Debieuvre D, Cadranel J, Lena H, Moro-Sibilot D, Chouaid C, Mennecier B, Urban T, Sagan C, Perrier L, Barlesi F, Denis MG. Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial. Clin Lung Cancer. 2020;21(1):e10-e14.
Gibiot Q, Monnet I, Levy P, Brun A-L, Antoine M, Chouaid C, Cadranel J, Naccache J-M. Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study. J Clin Med. 2020;9(3).

2019

Hurtaud A, Aubin M, Ferrat E, Lebreton J, Paillaud E, Audureau E, Bastuji-Garin S, Chouaid C, Boisnault P, Clerc P, Canoui-Poitrine F. Continuity of care in general practice at cancer diagnosis (COOC-GP study): a national cohort study of 2853 patients. Br J Gen Pract. 2019;69(679):e88-e96.
Bourdin A, Fabry-Vendrand C, Ostinelli J, Ait-Yahia M, Darnal E, Bouée S, Laurendeau C, Bureau I, Gourmelen J, Chouaid C. The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database. J Allergy Clin Immunol Pract. 2019;7(5):1477-1487.
Dalon F, Devouassoux G, Belhassen M, Nachbaur G, Da Silva CCorreia, Sail L, Jacoud F, Chouaid C, Van Ganse E. Impact of Therapy Persistence on Exacerbations and Resource Use in Patients Who Initiated COPD Therapy. Int J Chron Obstruct Pulmon Dis. 2019;14:2905-2915.
Tison A, Quere G, Misery L, Funck-Brentano E, Danlos F-X, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac J-B, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M. Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. Arthritis Rheumatol. 2019;71(12):2100-2111.
Chouaid C, Bensimon L, Clay E, Millier A, Lévy-Bachelot L, Huang M, Levy P. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019;127:44-52.
Delva F, Laurent F, Paris C, Belacel M, Brochard P, Bylicki O, Chouaid C, Clin B, Dewitte J-D, Le Denmat V, Gehanno J-F, Lacourt A, Margery J, Verdun-Esquer C, Mathoulin-Pelissier S, Pairon J-C. LUCSO-1-French pilot study of LUng Cancer Screening with low-dose computed tomography in a smokers population exposed to Occupational lung carcinogens: study protocol. BMJ Open. 2019;9(3):e025026.
Guyard A, Charpy C, Théou-Anton N, Cremades A, Grassin F, Bourgogne A, Leroy K, Pujals A, Copie-Bergman C, Chouaid C, Mansuet-Lupo A. Isolated 5' Signals Are an Atypical Pattern To Be Considered as Positive for ALK Rearrangement: A Brief Report of Three Cases and Review of the Literature. Transl Oncol. 2019;12(5):784-787.
Descourt R, Perol M, Rousseau-Bussac G, Planchard D, Mennecier B, Wislez M, Cortot A, Guisier F, Galland L, Do P, Schott R, Dansin E, Arrondeau J, Auliac J-B, Chouaid C. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). Lung Cancer. 2019;136:109-114.
Kissel M, Martel-Lafay I, Lequesne J, Faivre J-C, Le Péchoux C, Stefan D, Barraux V, Loiseau C, Grellard J-M, Danhier S, Lerouge D, Chouaid C, Gervais R, Thariat J. Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer. BMC Cancer. 2019;19(1):1237.
Chouaid C, Germain N, de Pouvourville G, Aballéa S, Korchagina D, Baldwin M, Le Lay K, Luciani L, Toumi M, Devillier P. Patient preference for chronic obstructive pulmonary disease (COPD) treatment inhalers: a discrete choice experiment in France. Curr Med Res Opin. 2019;35(5):785-792.
Bylicki O, Barazzutti H, Paleiron N, Margery J, Assié J-B, Chouaid C. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors. BioDrugs. 2019;33(2):159-171.
Chouaid C, Salaün M, Gounant V, Febvre M, Vergnon J-M, Jouniaux V, Fournier C, Lachkar S, Hermant C, Raspaud C, Quantin X, Quiot J-J, Molard A, Dayen C, Marquette C-H, Lena H, Zalcman G, Thiberville L. Clinical efficacy and cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration for preoperative staging of non-small-cell lung cancer: Results of a French prospective multicenter trial (EVIEPEB). PLoS One. 2019;14(1):e0208992.
Bylicki O, Didier M, Rivière F, Margery J, Grassin F, Chouaid C. Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care. BMJ Support Palliat Care. 2019;9(4):413-424.
Auliac J-B, Do P, Bayle S, Doubre H, Vinas F, Letreut J, Falchero L, Hauss PAlexandre, Thomas P, Chouaid C. Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02-14. Adv Ther. 2019;36(8):2161-2166.
Vayr F, Savall F, Bigay-Gamé L, Soulat J-M, Chouaid C, Hérin F. Lung cancer survivors and employment: A systematic review. Lung Cancer. 2019;131:31-39.
Auliac JBernard, Perol M, Planchard D, Monnet I, Wislez M, Doubre H, Guisier F, Pichon E, Greillier L, Mastroianni B, Decroisette C, Schott R, Le Moulec S, Arrondeau J, Cortot AB, Gérinière L, Renault A, Daniel C, Falchero L, Chouaid C. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation. Lung Cancer. 2019;127:96-102.
Auliac J-B, Saboundji K, André M, Madelaine J, Quere G, Masson P, Vergnenègre A, Lamy R, Raymond S, Chiappa A-M, Hauss P-A, Fournel P, Corre R, Chouaid C. Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. Target Oncol. 2019;14(3):307-314.
Ekman S, Griesinger F, Baas P, Chao D, Chouaid C, O'Donnell JC, Penrod JR, Daumont M, Lacoin L, McKenney A, Khovratovich M, Munro REj, Durand-Zaleski I, Johnsen SPaaske. I-O Optimise: a novel multinational real-world research platform in thoracic malignancies. Future Oncol. 2019;15(14):1551-1563.

2018

Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim S-W, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim D-W, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13(4):576-584.
Boyer L, Bastuji-Garin S, Chouaid C, Housset B, Le Corvoisier P, Derumeaux G, Boczkowski J, Maitre B, Adnot S, Audureau E. Are Systemic Manifestations Ascribable to COPD in Smokers? A Structural Equation Modeling Approach. Sci Rep. 2018;8(1):8569.
Schlemmer F, Boyer L, Soumagne T, Ridoux A, Chouaid C, Maitre B, Lanone S, Adnot S, Audureau E, Boczkowski J. Beclin1 circulating levels and accelerated aging markers in COPD. Cell Death Dis. 2018;9(2):156.
Saboundji K, Auliac J-B, Perol M, François G, Janicot H, Marcq M, Dubos-Arvis C, Renault A, Guisier F, Odier L, Gervais R, Chouaid C. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors. Target Oncol. 2018;13(4):501-507.
Locher C, Pourel N, Le Caer H, Bérard H, Auliac J-B, Monnet I, Descourt R, Vergnenègre A, Lafay IMartel, Greillier L, Chouaid C. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06). Lung Cancer. 2018;121:25-29.
Scherpereel A, Durand-Zaleski I, Cotté F-E, Fernandes J, Debieuvre D, Blein C, Gaudin A-F, Tournier C, Vainchtock A, Chauvin P, Souquet P-J, Westeel V, Chouaid C. Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study. BMC Cancer. 2018;18(1):1013.
Naccache J-M, Gibiot Q, Monnet I, Antoine M, Wislez M, Chouaid C, Cadranel J. Lung cancer and interstitial lung disease: a literature review. J Thorac Dis. 2018;10(6):3829-3844.
Lesueur P, Escande A, Thariat J, Vauléon E, Monnet I, Cortot A, Lerouge D, Danhier S, Do P, Dubos-Arvis C, Chouaid C, Gervais R. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC. Cancer Med. 2018;7(11):5505-5513.
Garassino MChiara, Cho B-C, Kim J-H, Mazières J, Vansteenkiste J, Lena H, Jaime JCorral, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018;19(4):521-536.
Bigay-Gamé L, Bota S, Greillier L, Monnet I, Madroszyk A, Corre R, Mastroianni B, Falchero L, Mazières J, Colineaux H, Lepage B, Chouaid C. Characteristics of Lung Cancer in Patients Younger than 40 Years: A Prospective Multicenter Analysis in France. Oncology. 2018;95(6):337-343.
Gauvain C, Vauléon E, Chouaid C, Le Rhun E, Jabot L, Scherpereel A, Vinas F, Cortot ABenjamin, Monnet I. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer. 2018;116:62-66.
Meyer G, Besse B, Doubre H, Charles-Nelson A, Aquilanti S, Izadifar A, Azarian R, Monnet I, Lamour C, Descourt R, Oliviero G, Taillade L, Chouaid C, Giraud F, Falcoz P-E, Revel M-P, Westeel V, Dixmier A, Trédaniel J, Dehette S, Decroisette C, Prevost A, Pichon E, Fabre E, Soria J-C, Friard S, Stern J-B, Jabot L, Dennewald G, Pavy G, Petitpretz P, Tourani J-M, Alifano M, Chatellier G, Girard P. Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial. Eur Respir J. 2018;52(4).
Babey H, Quere G, Descourt R, Le Calloch R, Lanfranco L, Nousbaum J-B, Cornec D, Tison A, Chouaid C. Immune-checkpoint inhibitors to treat cancers in specific immunocompromised populations: a critical review. Expert Rev Anticancer Ther. 2018;18(10):981-989.
Lesueur P, Martel-Laffay I, Escande A, Kissel M, Locher C, Gervais R, Schott R, Vergnenègre A, Chouaid C. Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review. Expert Rev Anticancer Ther. 2018;18(11):1159-1165.
Vergnenègre A, Chouaid C. Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC). Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):519-528.
Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018;124:310-316.
Bylicki O, Paleiron N, Rousseau-Bussac G, Chouaid C. New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. Onco Targets Ther. 2018;11:4051-4064.
Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue M-H, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Lung Cancer. 2018;124:298-309.
Bennouna J, Falchero L, Schott R, Bonnetain F, Coudert M, Yahia BBen Hadj, Chouaid C. Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE). Oncology. 2018;94(1):55-64.
Costantini A, Corny J, Fallet V, Renet S, Friard S, Chouaid C, Duchemann B, Giroux-Leprieur E, Taillade L, Doucet L, Nguenang M, Jouveshomme S, Wislez M, Trédaniel J, Cadranel J. Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer. ERJ Open Res. 2018;4(2).
Corre R, Gervais R, Guisier F, Tassy L, Vinas F, Lamy R, Fraboulet G, Greillier L, Doubre H, Descourt R, Chouaid C, Auliac J-B. Octogenarians with EGFR-mutated non-small cell lung cancer treated by tyrosine-kinase inhibitor: a multicentric real-world study assessing tolerance and efficacy (OCTOMUT study). Oncotarget. 2018;9(9):8253-8262.
Chouaid C, Assié JBaptiste, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JClaude. Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis. Cancer Med. 2018;7(4):1102-1109.
Cadranel J, Cortot AB, Lena H, Mennecier B, Do P, Dansin E, Mazières J, Chouaid C, Perol M, Barlesi F, Robinet G, Friard S, Thiberville L, Audigier-Valette C, Vergnenègre A, Westeel V, Slimane K, Buturuga A, Moro-Sibilot D, Besse B. Real-life experience of ceritinib in crizotinib-pretreated advanced non-small cell lung cancer patients. ERJ Open Res. 2018;4(1).

2017

Toumi M, Motrunich A, Millier A, Rémuzat C, Chouaid C, Falissard B, Aballéa S. Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment. J Mark Access Health Policy. 2017;5(1):1344088.
Taipale K, Winfree KB, Boye M, Basson M, Sleilaty G, Eaton J, Evans R, Chouaid C. A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res. 2017;9:505-518.
Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, Le Corvoisier P, Lino A, Covali-Noroc A, Housset B, Chouaid C, Maitre B, Levy Y, Lelièvre J-D, Adnot S. Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients. J Allergy Clin Immunol. 2017;140(6):1754-1757.e6.
Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. J Thorac Oncol. 2017;12(10):1496-1502.
Chouaid C, Loirat D, Clay E, Millier A, Godard C, Fannan A, Lévy-Bachelot L, Angevin E. Cost analysis of adverse events associated with non-small cell lung cancer management in France. Clinicoecon Outcomes Res. 2017;9:443-449.
Chouaid C, Debieuvre D, Durand-Zaleski I, Fernandes J, Scherpereel A, Westeel V, Blein C, Gaudin A-F, Ozan N, Leblanc S, Vainchtock A, Chauvin P, Cotté F-E, Souquet P-J. Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study). PLoS One. 2017;12(8):e0182798.
Bylicki O, Paleiron N, Margery J, Guisier F, Vergnenègre A, Robinet G, Auliac J-B, Gervais R, Chouaid C. Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer. Target Oncol. 2017;12(5):563-569.
Baize N, Monnet I, Greillier L, Quere G, Kerjouan M, Janicot H, Vergnenègre A, Auliac JBernard, Chouaid C. Second-line treatments of small-cell lung cancers. Expert Rev Anticancer Ther. 2017;17(11):1033-1043.
Le Caer H, Borget I, Corre R, Locher C, Raynaud C, Decroisette C, Bérard H, Audigier-Valette C, Dujon C, Auliac JBernard, Crequit J, Monnet I, Vergnenègre A, Chouaid C. Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. J Thorac Dis. 2017;9(10):3747-3754.
Auliac J-B, Monnet I, Dubos-Arvis C, Chiappa AMarie, Baize N, Bota S, Vergnenègre A, Doubre H, Locher C, Bizieux A, Robinet G, Chouaid C. Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02-14 Study). Target Oncol. 2017;12(6):833-838.
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S. Association between lung cancer somatic mutations and occupational exposure in never-smokers. Eur Respir J. 2017;50(4).
Tordrup D, Chouaid C, Cuijpers P, Dab W, van Dongen JMaria, Espin J, Jönsson B, Léonard C, McDaid D, McKee M, Miguel JPereira, Patel A, Reginster J-Y, Ricciardi W, van Molken MRutten-, Rupel VPrevolnik, Sach T, Sassi F, Waugh N, Bertollini R. PRIORITIES FOR HEALTH ECONOMIC METHODOLOGICAL RESEARCH: RESULTS OF AN EXPERT CONSULTATION. Int J Technol Assess Health Care. 2017;33(6):609-619.
Pignata M, Chouaid C, Le Lay K, Luciani L, McConnachie C, Gordon J, Roze S. Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France. Clinicoecon Outcomes Res. 2017;9:655-668.

2016

Quoix E, Lena H, Losonczy G, Forget F, Chouaid C, Papai Z, Gervais R, Ottensmeier C, Szczesna A, Kazarnowicz A, Beck JT, Westeel V, Felip E, Debieuvre D, Madroszyk A, Adam J, Lacoste G, Tavernaro A, Bastien B, Halluard C, Palanché T, Limacher J-M. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncol. 2016;17(2):212-223.
Paleiron N, Bylicki O, André M, Rivière E, Grassin F, Robinet G, Chouaid C. Targeted therapy for localized non-small-cell lung cancer: a review. Onco Targets Ther. 2016;9:4099-104.
Laforest L, Roche N, Devouassoux G, Belhassen M, Chouaid C, Ginoux M, Van Ganse E. Frequency of comorbidities in chronic obstructive pulmonary disease, and impact on all-cause mortality: A population-based cohort study. Respir Med. 2016;117:33-9.
Freyer G, Scotte F, Borget I, Bruyas A, Vainchtock A, Chouaid C. [Clinical burden caused by hospitalization for febrile neutropenia in France in 2010-2011: An analysis of the PMSI database]. Bull Cancer. 2016;103(6):552-60.
Fournel P, Vergnenègre A, Robinet G, Lena H, Gervais R, Le Caer H, Souquet P-J, Chavaillon J-M, Bozonnat M-C, Daurès J-P, Chouaid C, Martel-Lafay I. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01. Eur J Cancer. 2016;52:181-7.
Créquit P, Ruppert A-M, Rozensztajn N, Gounant V, Vieira T, Poulot V, Antoine M, Chouaid C, Wislez M, Cadranel J, Lavole A. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. Lung Cancer. 2016;96:74-7.
Corre R, Lena H, Vergnenègre A, Chouaid C. Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al. J Clin Oncol. 2016;34(33):4050-4051.
Corre R, Greillier L, Le Caer H, Audigier-Valette C, Baize N, Bérard H, Falchero L, Monnet I, Dansin E, Vergnenègre A, Marcq M, Decroisette C, Auliac J-B, Bota S, Lamy R, Massuti B, Dujon C, Perol M, Daurès J-P, Descourt R, Lena H, Plassot C, Chouaid C. Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study. J Clin Oncol. 2016;34(13):1476-83.
Chouaid C, Borget I, Braun E, Bazil M-L, Schaetz D, Rémuzat C, Toumi M. French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends. Target Oncol. 2016;11(4):515-34.
Atsou K, Créquit P, Chouaid C, Hejblum G. Simulation-Based Estimates of the Effectiveness and Cost-Effectiveness of Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease in France. PLoS One. 2016;11(6):e0156514.
Vinas F, Ben Hassen I, Jabot L, Monnet I, Chouaid C. Delays for diagnosis and treatment of lung cancers: a systematic review. Clin Respir J. 2016;10(3):267-71.
Vergnenègre A, Massuti B, de Marinis F, Carcereny E, Felip E, Do P, Sanchez JMiguel, Paz-Arez L, Chouaid C, Rosell R. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. J Thorac Oncol. 2016;11(6):801-7.

2015

Cittée J, Sauteron B, Brossier S, Ferrat E, Attali C, Chouaid C, Housset B. [COPD patient care pathways: points of view of hospital personnel]. Sante Publique. 2015;27(1 Suppl):S177-87.
Cittée J, Sauteron B, Brossier S, Ferrat E, Attali C, Chouaid C, Housset B. [In Process Citation]. Sante Publique. 2015;1 Suppl:177-87.
Chouaid C, Crequit P, Borget I, Vergnenègre A. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. Clinicoecon Outcomes Res. 2015;7:9-15.
Boyer L, Chouaid C, Bastuji-Garin S, Marcos E, Margarit L, Le Corvoisier P, Vervoitte L, Hamidou L, Frih L, Audureau E, Covali-Noroc A, Andujar P, Saakashvili Z, Lino A, Ghaleh B, Hue S, Derumeaux G, Housset B, Dubois-Randé J-L, Boczkowski J, Maitre B, Adnot S. Aging-related systemic manifestations in COPD patients and cigarette smokers. PLoS One. 2015;10(3):e0121539.
Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert A-M, Schott R, Lena H, Clément-Duchêne C, Quantin X, Souquet PJean, Trédaniel J, Moro-Sibilot D, Perol M, Madroszyk A-C, Soria J-C. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clin Cancer Res. 2015;21(8):1896-903.
Barlesi F, Chouaid C, Crequit J, Le Caer H, Pujol J-L, Legodec J, Vergnenègre A, Le Treut J, Fabre-Guillevin E, Loundou A, Auquier P, Simeoni M-C, Thomas PA. A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective. Interact Cardiovasc Thorac Surg. 2015;20(6):783-90.
Walzer S, Chouaid C, Lister J, Gultyaev D, Vergnenègre A, de Marinis F, Meng J, Carpeno Jde Castro, Crott R, Kleman M, Ngoh C. Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy. Expert Rev Anticancer Ther. 2015;15(1):121-8.
Toffart A-C, Dhalluin X, Girard N, Chouaid C, Audigier-Valette C, Duruisseaux M, Mennecier B, Parrot A, Fournel P, Moro-Sibilot D, Timsit J-F. Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units. Intensive Care Med. 2015;41(1):164-5.
Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C. A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Lung Cancer. 2015;90(3):397-404.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet P-J, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257-65.
Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet P-J, Barlesi F, Chouaid C, Molinier O, Bennouna J, Lavole A, Mazières J, Toffart A-C, Langlais A, Morin F, Zalcman G. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer. 2015;89(2):139-45.
Gervais R, Le Caer H, Monnet I, Falchero L, Baize N, Olivero G, Thomas P, Bérard H, Auliac JBernard, Chouaid C. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. Clin Lung Cancer. 2015;16(2):100-5.

2014

Lerouge D, Rivière A, Dansin E, Chouaid C, Dujon C, Schott R, Lavole A, Le Pennec V, Fabre E, Crequit J, Martin F, Dehette S, Fournel P, Precheur-Agulhon B, Lartigau E, Zalcman G. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer. 2014;14:231.
Chouaid C, Dujon C, Do P, Monnet I, Madroszyk A, Le Caer H, Auliac JBernard, Bérard H, Thomas P, Lena H, Robinet G, Baize N, Bizieux-Thaminy A, Fraboulet G, Locher C, Le Treut J, Hominal S, Vergnenègre A. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01). Lung Cancer. 2014;86(2):170-3.
Chouaid C, Borget I, Vergnenègre A. Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?. J Clin Oncol. 2014;32(31):3577.
Borget I, Perol M, Pérol D, Lavole A, Greillier L, Do P, Westeel V, Crequit J, Lena H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenègre A, Zalcman G, Chouaid C. Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study. BMC Cancer. 2014;14:953.

2013

Doz M, Chouaid C, Com-Ruelle L, Calvo E, Brosa M, Robert J, Decuypère L, Pribil C, Huerta A, Detournay B. The association between asthma control, health care costs, and quality of life in France and Spain. BMC Pulm Med. 2013;13:15.
Chouaid C, Le Caer H, Corre R, Crequit J, Locher C, Falchero L, Dujon C, Bérard H, Monnet I, Vergnenègre A. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505). Clin Lung Cancer. 2013;14(2):103-7.
Chouaid C, Agulnik J, Goker E, Herder GJM, Lester JF, Vansteenkiste J, Finnern HW, Lungershausen J, Eriksson J, Kim K, Mitchell PLR. Health-related quality of life and utility in patients with advanced non-small-cell lung cancer: a prospective cross-sectional patient survey in a real-world setting. J Thorac Oncol. 2013;8(8):997-1003.
Bylicki O, Ferlay C, Chouaid C, Lavole A, Barlesi F, Dubos C, Westeel V, Crequit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Perol M. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study. J Thorac Oncol. 2013;8(7):906-14.
Baud M, Strano S, Dechartres A, Jouni R, Triponez F, Chouaid C, Forgez P, Damotte D, Roche N, Régnard J-F, Alifano M. Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg. 2013;145(5):1305-11.
Vergnenègre A, Hominal S, Tchalla AEdem, Bérard H, Monnet I, Fraboulet G, Baize N, Audigier-Valette C, Robinet G, Oliviero G, Le Caer H, Thomas P, Gérinière L, Mastroianni B, Chouaid C. Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study). Lung Cancer. 2013;82(2):353-7.
Vergnenègre A, Borget I, Chouaid C. Treatment of lung cancer: will financial issues become a criterion of choice?. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):273-5.
Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thorac Oncol. 2013;8(12):1529-37.
Rittmeyer A, Gorbunova V, Vikström A, Scherpereel A, Kim J-H, Ahn M-J, Chella A, Chouaid C, Campbell AK, Barlesi F. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol. 2013;8(11):1409-16.
Prat L, Chouaid C, Kettaneh A, Fardet L. Cutaneous lymphangitis carcinomatosa in a patient with lung adenocarcinoma: case report and literature review. Lung Cancer. 2013;79(1):91-3.
Perol M, Pérol D, Chouaid C. Reply to N. Singh et al. J Clin Oncol. 2013;31(9):1251-2.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013;31(16):1997-2003.